Bicalutamide (marketed as Casodex Cosudex Calutide Kalumid) is an oral non-steroidal anti-androgen used in the treatment of prostate cancer and hirsutism. It was first launched in 1995 as a combination treatment (with surgical or medical castration) for advanced prostate cancer and subsequently launched as monotherapy for the treatment of earlier stages of the disease.Bicalutamide is marketed by AstraZeneca with the brand names Casodex and Cosudex.
This page contains content from the copyrighted Wikipedia article "Bicalutamide"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
